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Cost data:
The direct costs were those for insulin treatment, blood glucose strips, and the management of long-term diabetes complications (heart disease, stroke, myocardial infarction, heart failure, amputation, blindness, and renal failure). Costs of managing long-term complications came from the Ontario Ministry of Health and previously published studies. Costs of treatments were from the price of the lowest cost alternative for each drug class. Costs of blood glucose test strips came from a previously published study. All costs were updated to 2009 prices using the Health Component of the Canadian Consumer Price Index and were discounted at an annual rate of 5%. Costs were reported in Canadian Dollars (CAD).
Analysis of uncertainty:
A series of one-way and multi-way sensitivity analyses were undertaken. The estimates varied were: clinical effects, costs of treatments, treatment dosage, time horizon, discount rate, use of blood glucose strips, quality of life, event rates of hypoglycaemia, and adverse events. Cost-effectiveness acceptability curves were generated to illustrate the probability of each intervention being cost-effective across a range of cost-effectiveness thresholds.
Results
For metformin monotherapy, the average cost per patient was CAD 39,924 and the average QALYs gained were 8.72.
For metformin plus sulphonylureas, the average cost per patient was 40,669 and the average QALYs gained were 8.78.
For metformin plus meglitinide, the average cost per patient was CAD 42,269 and the average QALYs gained were 8.77.
For metformin plus alpha-glucosidase inhibitor, the average cost per patient was CAD 42,797 and the average QALYs gained were 8.78.
For metformin plus thiazolidinedione, the average cost per patient was CAD 46,202 and the average QALYs gained were 8.78.
For metformin plus dipeptidyl peptidase-4, the average cost per patient was CAD 47,191 and the average QALYs gained were 8.78.
For metformin plus basal insulin, the average cost per patient was CAD 47,348 and the average QALYs gained were 8.77.
For metformin plus biphasic insulin, the average cost per patient was CAD 52,367 and the average QALYs gained were 8.78.
Costs and benefits were combined using an incremental cost-utility ratio (the additional cost per QALY gained). When compared with metformin monotherapy, metformin plus sulphonylurea was associated with an incremental cost per QALY gained of CAD 12,757. All other interventions were found to be dominated as they were less effective and more costly.
